Cantargia’s CAN04 product candidate show very good safety at high dose levels, paving the way for final GLP toxicity study in autumn 2016
Cantargia AB’s (“Cantargia”) CAN04 product candidate is undergoing the final tests prior to submission of the application for clinical trials. The recently completed study investigated repeated treatment with up to 100 mg/kg and showed a very good safety. All the documentation is thus in place for the final GLP (good laboratory practice) toxicity study, for which the study protocol has been prepared. Cantargia will perform additional process development studies to establish a strong foundation for long-term production. Cantargia has therefore chosen to postpone the start of the GLP toxicity